Johannes M. Heuckmann
Max Planck Society · 142 works · 7,128 citations · h-index 28
Top works
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
- Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
- Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
- Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
- Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
- Telomerase activation by genomic rearrangements in high-risk neuroblastoma
- Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
- CD74–NRG1 Fusions in Lung Adenocarcinoma
- Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
- Coordination of Structure-Specific Nucleases by Human SLX4/BTBD12 Is Required for DNA Repair
- ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
- A mechanistic classification of clinical phenotypes in neuroblastoma
- A framework for identification of actionable cancer genome dependencies in small cell lung cancer
- Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients
- Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer
- Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach
- Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data
- A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine